title: [Immunohistochemical hormonal mismatch and human epidermal growth factor type 2 [HER2] phenotype of brain metastases in breast cancer carcinoma compared to primary tumors].
abstract: BACKGROUND
  Phenotype changes between primary tumor and the corresponding brain metastases are recent reported data. Breast cancer, with biological markers predicting prognosis and guiding therapeutic strategy remains an interesting model to observe and evaluate theses changes. The objective of our study was to compare molecular features (estrogen receptor [ER], progesterone receptor [PR], and human epidermal growth factor receptor type 2, [HER2]) between brain metastases and its primary tumor in patients presenting with pathologically confirmed breast cancer.
  
  
  METHODS
  This retrospective study was based on the immunohistochemical analysis of the brain metastases paraffin embedded samples stored in our institutional tumor bank, after surgical resection. The level of expression of hormonal receptors and HER2 on brain metastases were centrally reviewed and compared to the expression status in primary breast cancer from medical records.
  
  
  RESULTS
  Forty-four samples of brain metastases were available for analysis. Hormonal receptor modification status was observed in 11/44 brain metastases (25%) for ER and 6/44 (13.6%) for PR. A modification of HER2 overexpression was observed in brain metastases in 6/44 (13.6%). Molecular subtype modification was shown in 17 cases (38.6%). A significant difference was demonstrated between time to develop brain metastases in cases without status modification (HER2, ER and PR) (med=49.5months [7.8-236.4]) and in cases in which brain metastases status differs from primary tumor (med=27.5months [0-197.3]), (P=0.0244, IC95=3.09-51.62, Mann and Whitney test).
  
  
  CONCLUSIONS
  the main interest of this study was to focus on the molecular feature changes between primary tumor and their brain metastases. Time to develop brain metastases was correlated to phenotypic changes in brain metastases.
authors.affiliation: Département de neurochirurgie, Aix-Marseille université, CHU Timone, AP-HM, 264, rue Saint-Pierre, 13005 Marseille cedex 05, France.
authors.forename: C
authors.initials: C
authors.lastname: Joubert
authors.affiliation: Département de neurochirurgie, Aix-Marseille université, CHU Timone, AP-HM, 264, rue Saint-Pierre, 13005 Marseille cedex 05, France.
authors.forename: S
authors.initials: S
authors.lastname: Boissonneau
authors.affiliation: Inserm UMR 911, CRO2, Aix-Marseille université, Marseille, France; Laboratoire de transfert d'oncologie biologique, Aix-Marseille université, AP-HM, Marseille, France.
authors.forename: F
authors.initials: F
authors.lastname: Fina
authors.affiliation: Laboratoire de transfert d'oncologie biologique, Aix-Marseille université, AP-HM, Marseille, France; Département d'anatomie pathologique, Aix-Marseille Université, CHU Timone, AP-HM, Marseille, France.
authors.forename: D
authors.initials: D
authors.lastname: Figarella-Branger
authors.affiliation: Inserm UMR 911, CRO2, Aix-Marseille université, Marseille, France; Laboratoire de transfert d'oncologie biologique, Aix-Marseille université, AP-HM, Marseille, France.
authors.forename: L
authors.initials: L
authors.lastname: Ouafik
authors.affiliation: Département de neurochirurgie, Aix-Marseille université, CHU Timone, AP-HM, 264, rue Saint-Pierre, 13005 Marseille cedex 05, France.
authors.forename: S
authors.initials: S
authors.lastname: Fuentes
authors.affiliation: Département de neurochirurgie, Aix-Marseille université, CHU Timone, AP-HM, 264, rue Saint-Pierre, 13005 Marseille cedex 05, France.
authors.forename: H
authors.initials: H
authors.lastname: Dufour
authors.affiliation: Département d'oncologie moléculaire, centre de lutte contre le cancer, institut Paoli-Calmettes, Marseille, France.
authors.forename: A
authors.initials: A
authors.lastname: Gonçalves
authors.affiliation: Département d'anatomie pathologique, centre de lutte contre le cancer, institut Paoli-Calmettes, Marseille, France.
authors.forename: E
authors.initials: E
authors.lastname: Charaffe-Jauffret
authors.affiliation: Département de neurochirurgie, Aix-Marseille université, CHU Timone, AP-HM, 264, rue Saint-Pierre, 13005 Marseille cedex 05, France; Inserm UMR 911, CRO2, Aix-Marseille université, Marseille, France. Electronic address: pmetellus72@gmail.com.
authors.forename: P
authors.initials: P
authors.lastname: Metellus
mesh_terms: D000230:Adenocarcinoma / Q000737:chemistry / Q000556:secondary* / Q000628:therapy; D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000032:analysis*; D001932:Brain Neoplasms / Q000737:chemistry / Q000556:secondary* / Q000628:therapy; D001943:Breast Neoplasms / Q000737:chemistry* / Q000473:pathology / Q000628:therapy; D003131:Combined Modality Therapy; D004967:Estrogens; D005260:Female; D006801:Humans; D016130:Immunophenotyping; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000032:analysis*; D009376:Neoplasms, Hormone-Dependent / Q000737:chemistry / Q000556:secondary*; D011374:Progesterone; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis*; D011960:Receptors, Estrogen / Q000032:analysis; D011980:Receptors, Progesterone / Q000032:analysis; D012189:Retrospective Studies; D013997:Time Factors
chemical_list: D014408:Biomarkers, Tumor; D004967:Estrogens; D009363:Neoplasm Proteins; D011374:Progesterone; D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; C508053:ERBB2 protein, human
keywords: Brain metastases; Breast cancer; Cancer du sein; HER2; Hormonal receptor; Immunochemistry; Immunohistochimie; Métastases cérébrales; Récepteurs hormonaux